Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P W M Johnson

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
British Journal of Cancer|October 1, 2008
Survival from non-Hodgkin lymphoma in England and Wales up to 2001P W M Johnson
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2008
New targets for lymphoma treatmentP W M Johnson
Hematological Oncology|June 19, 2007
Primary mediastinal B-cell lymphomaE Boleti, P W M Johnson
Apoptosis : an International Journal on Programmed Cell Death|January 3, 2003
Differential regulation of cell survival by CD40C Dallman, P W M Johnson, G Packham
Leukemia|January 27, 2006
Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?K J McCann, P W M Johnson, F K Stevenson, et al.
British Journal of Cancer|August 30, 2008
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?L Nolan, P W M Johnson, A Ganesan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 18, 2009
Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519)W S Owadally, M R Sydes, J A Radford, et al.
Oncogene|September 20, 2006
Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytesF Habens, A S Lapham, C L Dallman, et al.
British Journal of Haematology|June 17, 2026
Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 studyL Ceriani, L Milan, L Cascione, et al.
Oncogene|August 23, 2006
Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cellsB M Pickering, S de Mel, M Lee, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
British Journal of Cancer|October 1, 2008
Survival from non-Hodgkin lymphoma in England and Wales up to 2001P W M Johnson
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2008
New targets for lymphoma treatmentP W M Johnson
Hematological Oncology|June 19, 2007
Primary mediastinal B-cell lymphomaE Boleti, P W M Johnson
Apoptosis : an International Journal on Programmed Cell Death|January 3, 2003
Differential regulation of cell survival by CD40C Dallman, P W M Johnson, G Packham
Leukemia|January 27, 2006
Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?K J McCann, P W M Johnson, F K Stevenson, et al.
British Journal of Cancer|August 30, 2008
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?L Nolan, P W M Johnson, A Ganesan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 18, 2009
Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519)W S Owadally, M R Sydes, J A Radford, et al.
Oncogene|September 20, 2006
Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytesF Habens, A S Lapham, C L Dallman, et al.
British Journal of Haematology|June 17, 2026
Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 studyL Ceriani, L Milan, L Cascione, et al.
Oncogene|August 23, 2006
Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cellsB M Pickering, S de Mel, M Lee, et al.
Pageof 2